GLOSSARY

Clinical trial terms used in this CRO RFI guide

Phase IIb / III trial
Late-stage efficacy and confirmatory clinical trials in patients prior to regulatory submission (NDA/BLA). Shortlisted CROs use varying labels (such as IQVIA’s “Phase IIb/III Trials”, Parexel’s Phase IIb-IV, or Precision’s Phase 2b-4 pivotal). IQVIA record.
Full-Service Outsourcing (FSO) vs. Functional Service Provider (FSP)
In FSO, one CRO manages end-to-end trial operations under a unified contract. In FSP, the sponsor retains overall study control and hires specialized functional teams (e.g., biostatistics, monitoring, data management).
Accellacare in-home service
ICON’s named decentralized/in-home clinical visit service (“all phases”). Vendor page claim tied to Accellacare in-home services; does not establish general CRO phase experience, sponsor-specific delivery or outcomes. ICON record.
Trial rescue / transition study
Transferring an ongoing clinical trial from one CRO to another due to enrollment delays, quality issues, or M&A disruption. Reviewed statements include Worldwide Clinical Trials (“Phase I-IV trial execution, RWE, and Transition Studies (mid-trial rescue)”) and Veristat (“specialty CRO combining regulatory advisory, biostatistics/InStat, clinical operations, DCT, and clinical trial rescue”). Worldwide record · Veristat record.
Pass-through costs & change orders
Direct third-party trial expenses (investigator site grants, central labs, travel, IRB fees) billed outside CRO management fees, and contract amendments triggered when protocol scope or timelines shift.

See all dated source records · ← Back to overview